Research programme: immuno-modulatory antibodies - ImCheck Therapeutics

Drug Profile

Research programme: immuno-modulatory antibodies - ImCheck Therapeutics

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator ImCheck Therapeutics
  • Class Antibodies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Immunological disorders

Most Recent Events

  • 17 May 2017 Early research in Cancer in France (Parenteral) before May 2017 (ImCheck Therapeutics pipeline, May 2017)
  • 17 May 2017 Early research in Immunological disorders in France before May 2017 (Parenteral) (ImCheck Therapeutics pipeline, May 2017)
  • 17 May 2017 ImCheck Therapeutics plans a phase I trial for Cancer and Immunological disorders (ImCheck Therapeutics pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top